About Us

About Us

Palisade Bio is a biopharmaceutical company focused on identifying and developing therapeutics that protect the integrity of the intestinal barrier. The Company believes that addressing the disruption of the intestinal barrier can fundamentally change the way diseases are treated and establish new standards of patient care.

The Company recently entered into an exclusive worldwide licensing agreement with Giiant Pharma, Inc. for multiple oral drug candidates targeting inflammatory bowel disease (IBD) and a proprietary precision delivery technology platform. IBD represents a multi-billion-dollar market opportunity in need of innovative approaches, with current therapies achieving a clinical remission rate of less than 20% on average.

Palisade Bio’s lead program, PALI-2108 is a microbiota-activated PDE4 inhibitor prodrug being developed for the treatment of moderate-to-severe ulcerative colitis and is advancing toward the completion of IND-enabling studies and an IND filing. The Company’s second lead program, PALI-1908, is being evaluated in preclinical development for the treatment of fibro stenotic Crohn’s Disease.

Intestinal Villi

Leadership Team

Our leadership is comprised of a team of experts in clinical development, commercialization, and pipeline development who are passionate about the advancement of science and medicine.

Ryker Willie

Senior Vice President, Finance and Corporate Controller

Board Of Directors

Clinical Advisory Board

Scientific Advisory Board

Careers

The Palisade Bio team is dedicated to identifying and developing new therapies for a range of serious, widespread health conditions that impact millions of patients every year. We are driven by science—and supported by a culture of innovation, openness and problem-solving.

Join us in our mission.